ClinicalTrials.gg
CompletedNCT00533702Updated Aug 1, 2014Results posted

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

A Phase 2 interventional study of IMC-1121B (ramucirumab) and Dacarbazine in Metastatic Malignant Melanoma, sponsored by Eli Lilly and Company. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-01.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Melanoma by Eli Lilly and Company — none open to participants now, 1 under way, none of them phase 3. Melanoma · Eli Lilly and Company.

Enrollment
8th of 13
106 · median 130
Started
2007
the only one that year
Phase 2
3 of 14
none open now
Registered
3rd of 14
by date

Among the 14 studies in Melanoma by Eli Lilly and Company, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2, and was the 3rd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 14 studies in Melanoma by Eli Lilly and Company is open now. The open studies under Melanoma, anywhere →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Melanoma by Eli Lilly and Company as a file.
02

Study summary

The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.

Read the detailed description

The purpose of this study is to determine the antitumor activity and safety profile of IMC-1121B (ramucirumab) when used alone or in combination with dacarbazine in participants with metastatic melanoma who have not received prior chemotherapy for this disease.

03

Conditions studied

  • Metastatic Malignant Melanoma

Browse trials for

Keywords

  • Phase II
  • Melanoma
  • IMC-1121B
  • ImClone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has or cytologically confirmed melanoma that is stage IV ()
  • The participant has an Eastern Cooperative Oncology Performance Status ( PS) of 0-1
  • The participant has completed any prior radiotherapy, biologic/immunotherapy or vaccine therapy (for adjuvant or advanced disease) at least six weeks prior to the first dose of study therapy
  • The participant has adequate hematological functions [ (ANC) ≥ 1500 cells/microliter (μL), ≥ 9 grams/deciliter (g/dL) and ≥ 100,000 cells/μL].
  • The participant has adequate hepatic function [ within normal limits (WNL), (AST) and/or alanine transaminase (ALT) ≤ 2.5 times the (ULN), or ≤ 5.0 times the ULN if the transaminase elevation is due to liver metastases]
  • The participant has serum creatinine ≤ 1.5 x ULN [or a calculated > 60 milliliters/minute (mL/min)]
  • The participant's urinary protein ≤ 1+ on dipstick or routine urinalysis [(UA); if urine dipstick or routine analysis is ≥ 2+, a 24-hour urine for protein must demonstrate \< 1000 milligrams (mg) of protein in 24 hours to allow participation in the study]
  • The participant must have adequate coagulation function as defined by (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 1.5 X ULN

Exclusion criteria

Exclusion Criteria

  • The participant has mucosal or intra-ocular melanoma
  • The participant has known or suspected brain or
  • The participant has had prior cytotoxic chemotherapy for malignant melanoma
  • The participant has had more than one line of biologic, immunologic or vaccine-based therapy for metastatic malignant melanoma (including therapy for adjuvant or advanced disease)
  • The participant has a nonhealing wound or ulcer
  • The participant has a known alcohol or drug dependency
  • The participant is pregnant or breastfeeding
  • The participant has a coexisting medical or psychiatric problem of sufficient severity to limit compliance with the study and/or increase the risks associated with study participation or study drug administration or interfere with the interpretation of study results
  • The participant has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    IMC-1121B (ramucirumab)

    IMC-1121B (ramucirumab)

    Biological: IMC-1121B (ramucirumab)

  • Active comparator
    IMC-1121B (ramucirumab) + dacarbazine

    IMC-1121B (ramucirumab) + dacarbazine

    Biological: IMC-1121B (ramucirumab) · Drug: Dacarbazine

Interventions

  • 10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.

    Also known as: ramucirumab, LY3009806

  • 1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.

    Also known as: DIC, Imidazole, Carboxamide

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the first day of therapy to the first evidence of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause. Progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameter (LD) of the target lesions, taking as reference the smallest sum LD recorded since the treatment started in comparison with the measurement of the nadir or the appearance of 1 or more new lesions. In addition, unequivocal progression of existing non-target lesions was considered PD. New or existing pleural effusion/ascites required cytological confirmation for PD according to the protocol. Participants who did not progress and who were alive or did not have documented progression or missed ≥2 visits, or had no post baseline assessment were censored at the day of their last tumor assessment.

    Time frame: Baseline up to 36 months

Secondary outcomes

  1. Number of Participants With Adverse Events (AE)

    The number of participants who experienced any IMC-1121B (ramucirumab \[RAM\]) treatment-related and treatment emergent AE (TEAE), treatment-related TEAE of Grade ≥3, treatment-related TE serious AEs (SAEs), treatment-related TEAE resulting in death (Grade 5 AE) and any TEAEs resulting in death. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline up to 40 months

  2. Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]

    The ORR was defined as the percentage of all randomized participants with the best overall response of PR or CR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions. PR was defined as at least a 30% decrease in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met.

    Time frame: Cycle 1 Day 1 (of 21-day cycle) up to 17.1 months

  3. Duration of Response

    The duration of overall response was defined as the time from first assessment of complete response (CR) or partial response (PR) to the first date of progressive disease (PD) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), initiation of other or additional antitumor therapy, or death from any cause. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. PD was defined as at least 20% increase in sum of longest diameter of target lesions. Participants who did not relapse were censored at the day of their last objective tumor assessment.

    Time frame: Cycle 1 Day 1 (of 21-day cycle) up to 17.1 months

  4. Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 6 Weeks

    Disease Control Rate (DCR) was defined as complete response (CR) plus partial response (PR) plus SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. SD was defined as: neither sufficient increase to qualify for progressive disease (PD) nor sufficient shrinkage to qualify for PR, taking as reference the smallest sum of the longest diameters recorded since treatment began. PD was defined as at least 20% increase in sum of longest diameter of target lesions.

    Time frame: 6 weeks (2 cycles of treatment)

  5. Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 12 Weeks

    Disease Control Rate (DCR) was defined as complete response (CR) plus partial response (PR) plus SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. Stable Disease (SD) was defined as: neither sufficient increase to qualify for progressive disease (PD) nor sufficient shrinkage to qualify for PR, taking as reference the smallest sum of the longest diameters recorded since treatment began. PD was defined as at least 20% increase in sum of longest diameter of target lesions.

    Time frame: 12 weeks (4 cycles of treatment)

  6. Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) at 12 Weeks

    Response rate was defined as a CR or a PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met.

    Time frame: 12 weeks (4 cycles of treatment)

  7. Maximum Concentration (Cmax) for Cycle 1 Day 1

    Cmax was not calculated due to sparse sampling.

    Time frame: Cycle 1 Day 1 (21-day cycle) 1-hour post infusion

  8. Maximum Concentration (Cmax) for Cycle 1 Day 7

    Cmax was not calculated due to sparse sampling.

    Time frame: Cycle 1 Day 7 (21-day cycle)

  9. Maximum Concentration (Cmax) for Cycle 1 Day 14

    Cmax was not calculated due to sparse sampling.

    Time frame: Cycle 1 Day 14 (21-day cycle)

07

Results

Posted Jun 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
Started5452
Received any quantity of study drug5250
Completed4950
Not completed52
Withdrew: Withdrawal by subject31
Withdrew: Found ineligible after randomization21

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time from the first day of therapy to the first evidence of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause. Progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameter (LD) of the target lesions, taking as reference the smallest sum LD recorded since the treatment started in comparison with the measurement of the nadir or the appearance of 1 or more new lesions. In addition, unequivocal progression of existing non-target lesions was considered PD. New or existing pleural effusion/ascites required cytological confirmation for PD according to the protocol. Participants who did not progress and who were alive or did not have documented progression or missed ≥2 visits, or had no post baseline assessment were censored at the day of their last tumor assessment.

Time frame:
Baseline up to 36 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
Progression Free Survival (PFS)2.6 (1.4 to 5.4)1.7 (1.4 to 2.9)
SecondaryNumber of Participants With Adverse Events (AE)

The number of participants who experienced any IMC-1121B (ramucirumab \[RAM\]) treatment-related and treatment emergent AE (TEAE), treatment-related TEAE of Grade ≥3, treatment-related TE serious AEs (SAEs), treatment-related TEAE resulting in death (Grade 5 AE) and any TEAEs resulting in death. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline up to 40 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AE)
participantsIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
Any RAM related TEAE4340
RAM related SAE95
RAM related ≥ Grade 3 AE2013
RAM related death11
RAM related TEAE leading to discontinuation of RAM34
Any AE with outcome of death22
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]

The ORR was defined as the percentage of all randomized participants with the best overall response of PR or CR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions. PR was defined as at least a 30% decrease in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met.

Time frame:
Cycle 1 Day 1 (of 21-day cycle) up to 17.1 months
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
percentage of participantsIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]17.3 (8.2 to 30.3)4.0 (0.5 to 13.7)
SecondaryDuration of Response

The duration of overall response was defined as the time from first assessment of complete response (CR) or partial response (PR) to the first date of progressive disease (PD) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), initiation of other or additional antitumor therapy, or death from any cause. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. PD was defined as at least 20% increase in sum of longest diameter of target lesions. Participants who did not relapse were censored at the day of their last objective tumor assessment.

Time frame:
Cycle 1 Day 1 (of 21-day cycle) up to 17.1 months
Reported as:
Median · months
Duration of Response
monthsIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
Duration of Response11.0 (3.9 to 17.1)NA (3.2 to 14.0)
SecondaryPercentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 6 Weeks

Disease Control Rate (DCR) was defined as complete response (CR) plus partial response (PR) plus SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. SD was defined as: neither sufficient increase to qualify for progressive disease (PD) nor sufficient shrinkage to qualify for PR, taking as reference the smallest sum of the longest diameters recorded since treatment began. PD was defined as at least 20% increase in sum of longest diameter of target lesions.

Time frame:
6 weeks (2 cycles of treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 6 Weeks
percentage of participantsIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 6 Weeks5444
SecondaryPercentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 12 Weeks

Disease Control Rate (DCR) was defined as complete response (CR) plus partial response (PR) plus SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. Stable Disease (SD) was defined as: neither sufficient increase to qualify for progressive disease (PD) nor sufficient shrinkage to qualify for PR, taking as reference the smallest sum of the longest diameters recorded since treatment began. PD was defined as at least 20% increase in sum of longest diameter of target lesions.

Time frame:
12 weeks (4 cycles of treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 12 Weeks
percentage of participantsIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 12 Weeks4024
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) at 12 Weeks

Response rate was defined as a CR or a PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met.

Time frame:
12 weeks (4 cycles of treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) at 12 Weeks
percentage of participantsIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) at 12 Weeks13.54.0
SecondaryMaximum Concentration (Cmax) for Cycle 1 Day 1

Cmax was not calculated due to sparse sampling.

Time frame:
Cycle 1 Day 1 (21-day cycle) 1-hour post infusion

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) for Cycle 1 Day 7

Cmax was not calculated due to sparse sampling.

Time frame:
Cycle 1 Day 7 (21-day cycle)

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) for Cycle 1 Day 14

Cmax was not calculated due to sparse sampling.

Time frame:
Cycle 1 Day 14 (21-day cycle)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IMC-1121B (Ramucirumab) + Dacarbazine—14/52 (26.9%)52/52 (100%)
IMC-1121B (Ramucirumab)—15/50 (30%)48/50 (96%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
Infusion related reactionGeneral disorders0/523/50
Abdominal painGastrointestinal disorders0/522/50
Hepatic failureHepatobiliary disorders0/522/50
Coronary artery diseaseCardiac disorders0/521/50
Myocardial infarctionCardiac disorders0/521/50
Supraventricular tachycardiaCardiac disorders0/521/50
VomitingGastrointestinal disorders0/521/50
JaundiceHepatobiliary disorders0/521/50
DehydrationMetabolism and nutrition disorders0/521/50
Back painMusculoskeletal and connective tissue disorders0/521/50
Most frequent other events
Showing 10 of 61
Most frequent other events
EventIMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)
FatigueGeneral disorders33/5228/50
ThrombocytopeniaBlood and lymphatic system disorders20/524/50
NauseaGastrointestinal disorders20/5214/50
NeutropeniaBlood and lymphatic system disorders18/520/50
HeadacheNervous system disorders9/5216/50
ConstipationGastrointestinal disorders16/5210/50
Oedema peripheralGeneral disorders15/5210/50
AnorexiaMetabolism and nutrition disorders14/527/50
DyspnoeaRespiratory, thoracic and mediastinal disorders14/524/50
HypertensionVascular disorders12/5212/50

Baseline characteristics

All enrolled participants who were treated with any quantity of study drug.

Age, Categorical
Age, Categorical(Participants)IMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)Total
<=18 years000
Between 18 and 65 years292857
>=65 years232245
Sex: Female, Male
Sex: Female, Male(Participants)IMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)Total
Female151227
Male373875
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)Total
Hispanic or Latino516
Not Hispanic or Latino474996
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)IMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)Total
United States5250102
Race
Race(participants)IMC-1121B (Ramucirumab) + DacarbazineIMC-1121B (Ramucirumab)Total
Asian101
White5050100
Other101
08

Study locations

17 sites
  • ImClone Investigational Site
    Decatur, Alabama 35601, United States
  • ImClone Investigational Site
    Scottsdale, Arizona 85258, United States
  • ImClone Investigational Site
    Scottsdale, Arizona 85260, United States
  • ImClone Investigational Site
    Fresno, California 93720, United States
  • ImClone Investigational Site
    San Francisco, California 94109, United States
  • ImClone Investigational Site
    Aurora, Colorado 80045, United States
  • ImClone Investigational Site
    Jacksonville, Florida 32256, United States
  • ImClone Investigational Site
    Orlando, Florida 32806, United States
  • ImClone Investigational Site
    Oxford, Mississippi 38655, United States
  • ImClone Investigational Site
    Missoula, Montana 59806, United States
  • ImClone Investigational Site
    Buffalo, New York 14263, United States
  • ImClone Investigational Site
    New York City, New York 10016, United States
  • ImClone Investigational Site
    New York, New York 10021, United States
  • ImClone Investigational Site
    Willow Grove, Pennsylvania 19090, United States
  • ImClone Investigational Site
    Dallas, Texas 75230, United States
  • ImClone Investigational Site
    Houston, Texas 77030, United States
  • ImClone Investigational Site
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Rojas PB, Schwartz JD, Bedikian AY. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer. 2014 Aug;50(12):2099-107. doi: 10.1016/j.ejca.2014.03.289. Epub 2014 Jun 12. PubMed 24930625 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 1 month after primary completion. A results delay was requested in Sep 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2007
First posted
Sep 21, 2007
Start
Nov 2007
Primary completionActual
May 2011
CompletionActual
May 2011
Results delay requested
Sep 14, 2010
Results first posted
Jun 18, 2014
Last update
Aug 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00533702
Responsible party
Sponsor
First posted
Sep 21, 2007
Start date
Nov 2007
Primary completion
May 2011
Completion
May 2011
Results posted
Jun 18, 2014
Last update
Aug 1, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion